Lakeshore biopharma announces financial results for fiscal year 2024

Gross margin increased to 79.5%; product pipeline continues to advance company anticipates double-digit year-over-year revenue growth and bottom line breakeven for fiscal year 2025 gaithersburg, md. , aug. 15, 2024 /prnewswire/ -- lakeshore biopharma co., ltd.
LSB Ratings Summary
LSB Quant Ranking